The genesis of every company is the idea behind it.
Ours is simply redefining the treatment paradigm for patients with peripheral artery occlusions, DVT, or pulmonary embolism. How can we solve the shortcomings of traditional technologies, improve patient outcomes, and expand the number of patients who can benefit from peripheral endovascular thrombectomy? We were intrigued by the advantages of proximal clot ingestion with aspiration technology. The benefits were clear, but so were the limitations: blood loss, limited clot ingestion force, and limited ability to ingest organized clot among them.
Taking the benefits of proximal clot ingestion, we aimed at removing these obstacles, and our mechanical conveyor technology with the proprietary Devortex™ Sleeve was born. No longer limited by the clot ingestion force of typical aspiration technology, the WOLF Thrombectomy System efficiently removes both soft and organized clot – with no thrombolytics and no blood loss.
Devoro is privately held and was formed in 2018.
Board of Directors
Shangbay Capital and CEO, Lucira Health
Casper de Clercq
General Partner, Norwest Venture Partners
CEO, Vesper Medical
Co-Founder, Devoro Medical and CTO, TELA Bio
Michael P. Wallace
CEO & Co-Founder, Devoro Medical